Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice

Michael Dobosz
Steffen Strobel
Kay-Gunnar Stubenrauch
Franz Osl
Werner Scheuer
Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging in the eye of mice

Michael Dobosz,a Steffen Strobel,a Kay-Gunnar Stubenrauch,b Franz Osl,a and Werner Scheuer*a,*

Abstract. Purpose: For generating preclinical pharmacokinetics (PKs) of compounds, blood is drawn at different time points and levels are quantified by different analytical methods. In order to receive statistically meaningful data, 3 to 5 animals are used for each time point to get serum peak-level and half-life of the compound. Both characteristics are determined by data interpolation, which may influence the accuracy of these values. We provide a method that allows continuous monitoring of blood levels noninvasively by measuring the fluorescence intensity of labeled compounds in the eye and other body regions of anesthetized mice. Procedures: The method evaluation was performed with four different fluorescent compounds: (i) indocyanine green, a nontargeting dye; (ii) OsteoSense750, a bone targeting agent; (iii) tumor targeting Trastuzumab-Alexa750; and (iv) its F(ab')2-alxea750 fragment. The latter was used for a direct comparison between fluorescence imaging and classical blood analysis using enzyme-linked immunosorbent assay (ELISA). Results: We found an excellent correlation between blood levels measured by noninvasive eye imaging with the results generated by classical methods. A strong correlation between eye imaging and ELISA was demonstrated for the F(ab')2 fragment. Whole body imaging revealed a compound accumulation in the expected regions (e.g., liver, bone). Conclusions: The combination of eye and whole body fluorescence imaging enables the simultaneous measurement of blood PKs and biodistribution of fluorescent-labeled compounds. © The Authors. Published by SPIE under a Creative Commons Attribution 3.0 Unported License. Distribution or reproduction of this work in whole or in part requires full attribution of the original publication, including its DOI. [DOI: 10.1117/1.JBO.19.1.016022]

Keywords: near-infrared fluorescence imaging; eye-imaging; pharmacokinetics; biodistribution; peak-level; half-life.

Paper 130264R received Apr. 25, 2013; revised manuscript received Nov. 21, 2013; accepted for publication Dec. 5, 2013; published online Jan. 27, 2014.

1 Introduction

The study of the time course of a drug in the body is a key determinant in the selection of a drug candidate. In general, pharmacokinetic (PK) provides information that can guide future animals and clinical studies for the selection of the dose levels and frequency of administration.

Multiple steps are involved in PK studies, e.g., formulation, animal dosing and sampling, sample processing and analysis, and PK regression and data reporting. Blood samples are collected at several time points, concluding at one predose and/or multiple postdoses. Reliable analytical methods [e.g., enzyme-linked immunosorbent assay (ELISA), size exclusion chromatography (SEC), high-performance liquid chromatography, liquid scintillation counting using nonlabeled or radiolabeled compounds] are required to quantify the drug concentration in the samples and sometimes need to be developed first.

Following drug administration, the maximum observed concentration in the concentration–time profile ($C_{\text{max}}$) and the time to reach that peak-level ($t_{\text{max}}$) are important descriptors of the extent and nature of drug exposure. $C_{\text{max}}$ is an indicator of maximum drug exposure, may sometimes relate better to pharmacological or toxicological effects than the other measures of exposure. In the drug discovery setting, however, secondary or derived parameters such as half-life ($t_{1/2}$) or area under the curve (AUC) have increased practical importance. The half-life is generally used as a guide to determine the dose interval of a drug. The conventional PK studies use the dosing strategy of a single compound per animal to avoid potential problems of drug-drug interactions.

In addition, the trauma associated with the frequent venipuncture and blood loss could be expected to cause adverse changes in physiology, which could interfere with the findings of the PK parameters. A full preclinical PK study typically takes 6–12 serial blood samples from 6 to 8 animals/compound, which therefore requires a minimum of 36 samples/study. Because of the lower blood sampling volume allowed in the mouse, a full PK study in mice often requires twice the number of animals over that in a rat PK study. Consequently, many efforts are undertaken to optimize the throughput of PK studies, e.g., cassette dosing and snapshot PK. For generating the PK profile, serum drug concentration is plotted versus time by interpolation of the single time point data to generate the AUC. Inappropriate selection of time points or missing serum samples may complicate the interpolation which may influence the accuracy of the PK analysis. Finally, the determination of PK drug characteristics is laborious and error-prone because the measurement of different time points cannot be made in the same animal. These problems may lead to misinterpretation of the time course of a drug in the body.

Noninvasive imaging modalities such as positron emission tomography and single-photon emission computed tomography are applied in preclinical drug development to monitor the kinetics of drugs labeled with positron emitting radionuclides. Such studies have been extremely useful to ascertain their suitability as potential radiopharmaceuticals for humans, but are correlated with high costs, long acquisition times, and special
safety requirements for working with radioactivity. Furthermore, the exact determination of kinetic parameters requires manual blood/tissue sampling for counting the radioactivity emitting from the blood and from the tissue lysates, which is still the reference method for tracer concentration measurements. Especially, blood/tumor ratios are constructed based on such imaging studies to reveal the kinetics of tumor targeting antibodies or new antibody constructs.8,9

Near-infrared (NIR) optical imaging is a noninvasive, nonionizing, and real-time modality that is emerging as a diagnostic tool for different in vivo and ex vivo applications.8–10 This technique offers a simplistic while highly sensitive approach for molecular imaging research in a manner analogous to traditional approaches with radiolabeled agents. Recent studies indicate that this approach is feasible to measure the organ specific uptake dynamics of indocyanine green (ICG) and to assess the liver function after transient damage.11

In this study, we applied optical imaging in the planar reflectance mode since the NIR excitation light can penetrate into the eye of an animal with low tissue absorption and light scattering and thus illuminates the highly vascularized retina of the eye. This direct and unrestricted access to the blood vessels offers the possibility to noninvasively measure the fluorescence intensity of labeled compounds over the time in the same animal. The combination of eye imaging with the whole body fluorescence imaging enables the simultaneous measurement of blood PKs, biodistribution, and accumulation of labeled compounds over the time in different region of interests (ROI). Measurements can be performed serially, thus giving the possibility of PK analysis with a temporal resolution in the order of seconds. By multiple measurements over the time period of 2 h “kinetic movies” can be created, facilitating the mathematical description of different PK parameters. We performed a feasibility study to visualize noninvasively drug peak-levels, half-life in blood, accumulation to organs and saturation kinetics by using fluorescence-labeled drugs. The utility of this approach is demonstrated by evaluating the four different fluorescent compounds. Data generated by this method reveal excellent concordance with results obtained with the classical methods of PKs.

2 Materials and Methods

2.1 Compounds and Labeling

ICG, a nontargeting fluorescent dye was purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany) and OsteoSense750, a fluorescence-labeled bisphosphate targeting bone tissue was bought from PerkinElmer (Rodgau, Germany). Trastuzumab and the F(ab’)2 fragment of Trastuzumab were provided from Roche Diagnostics GmbH (Fenzberg, Germany). Both compounds were labeled in-house with the fluorochromes Alexa750 (Invitrogen, Hamburg, Germany) by mono-reactive N-hydroxysuccinimide ester to lysine residues with a labeling ratio of 3 fluorochromes/molecule. Labeled compounds were purified by the dialysis and SEC, and afterward surface plasmon resonance analysis (BiaCore, LKB, Bromma, Sweden) was performed to verify biological identity and binding characteristics. The results revealed no significant changes in the $k_a$ and $k_{off}$ constants and the resulting affinity between labeled and nonlabeled molecules.

2.2 Animals

All imaging experiments were performed in female severe combined immunodeficiency (SCID) hairless outbred (SHO) mice from Charles River, Germany (age: 6 to 8 weeks, weight: 20 to 25 g). The experimental study protocols were reviewed and approved by the local government. Mice were handled according to committed guidelines (GV-Solas; Felsa; TierschG) and the animal facility has been accredited by AALAC.

2.3 In Vivo Imaging

Mice received inhalation anesthesia and the compounds were administered i.v. through a tail vein catheter. The eyes of the mice were covet with custom-made contact lenses to prevent desiccation. ICG was injected either with a single dose [10 μg/100 μl phosphate-buffered saline (PBS), $n = 1$] and multiple injections of identical (3 × 10 μg/100 μl, $n = 1$) and escalating dosages (5 μg/50 μl, 10 μg/100 μl, and 15 μg/150 μl, $n = 1$). Fluorescence signal intensities (SIs) were recorded with a rate of 1 frame/s over a 6 min time period (exposure time: 500 ms; excitation (ex.) filter: 710 to 760 nm; emission (em.) filter: 830 to 840 nm). OsteoSense750 was injected into an SHO mouse with a single dose of 2 nMol/200 μl PBS and SIs were recorded every 5 s for 1.4 h (exposure time: 500 ms; ex. filter: 671 to 705 nm; em. filter: 770 to 780 nm). The Alexa750 labeled antibody Trastuzumab (n = 1) and its F(ab’)2 fragment (n = 8) were injected with a single dose of 50 μg/100 μl PBS. Due to the longer half-life of antibodies in mice, longer observation periods are required.12 Nevertheless, mice should not be held under anesthesia for >2 h and therefore 1 image/s was only acquired for 15 min (exposure time: 200 ms; ex. filter: 671 to 705 nm; em. filter: 770 to 780 nm). Thereafter, daily measurements were performed at different time points. Fluorescence SIs were monitored and analyzed with the MAESTRO imaging system (PerkinElmer, Rodgau, Germany). The measurements were started 10 s before compound injection and at the end of the study all acquired image cubes were spectrally unmixed. The measurement ROIs were set over specific areas of the animal and the average SIs were determined as scaled counts per second (sc/s). The first SI value received from the ROI of the eye which increased the background SI by 10-fold was defined as the zero point of the measurement. The acquired fluorescence SIs from the selected ROI were plotted over the time.

2.4 Blood Sampling and ELISA Analysis

After i.v. injection of the F(ab’)2-Alexa750 fragment in naive SHO mice (n = 8), fluorescence in vivo imaging was performed at different time points and blood samples were taken immediately afterward at 3, 8, and 24 h, respectively, from all animals. Thereafter, a solid phase Sandwich-ELISA was used to determine the concentration of human F(ab’)2-Alexa750 in mouse serum. The assay principle consists of the capture of the analyte by microtiter plate-bound antihuman kappa light chain Fab M-1.7.10 (Roche) and subsequent detection of the bound analyte by digoxigenylated antihuman CH1 domain Fab M-1.19.31 (Roche) which in turn is recognized by a horseradish peroxidase (HRP) labeled polyclonal antiDig antibody. The HRP of the polyclonal antibody catalyzes a color reaction of the substrate 2, 2'-azino-di(3-ethylbenzthiazoline-6-sulfonate). The color intensity is proportional to the concentration of the analyte. The dosing
material of the human F(\(ab^\prime\))_2 fragment was used for the preparation of calibration standards. The lower limit of quantification of the assay is 20 ng/ml.

3 Results

3.1 Method Evaluation with ICG

In order to evaluate the application of eye imaging for PK studies, we measured the average SI of ICG noninvasively over the time. This molecule provides a short half-life and a fast clearance rate and is therefore eminently suitable for repeated applications in the same experimental animal.

Data generated in an SHO mouse demonstrate that \(t_{\text{max}}\) of ICG was reached 10 s after i.v. injection and the half-life of the SI was 1.2 min (Fig. 1 and Video 1). The received half-life result is in concordance with the published data.\(^{13,14}\) The reproducibility of this method was assessed by administering multiple injections of equal ICG dosages in short intervals in the same animal [Fig. 2(a) and Video 2]. The acquired average SI of the three repeated ICG applications revealed a nearly identical curve shape and only slight peak-level variations. The \(t_{\text{max}}\) values are almost identical and were calculated to be 13 s (first application), 15 s (second application), and 15 s (third application), whereas the values for \(t_{1/2}\) were 1.8, 2.2, and 2.5 min, respectively [Fig. 2(b)]. The continuously increasing half-life values may be attributed to the limited clearing capacity of the liver and the cumulative dose effect of the three applications leading to an accumulation of ICG in the blood. In a second study, we examined if the injection of escalating dosages of ICG correlated with increased fluorescence SIs in the eye [Fig. 3(a) and Video 3]. The maximum peak-levels of all three applications occurred after 3 s, however, the half-life was starting slightly to increase after the third ICG application (1.4, 1.3, and 1.6 min, respectively) [Fig. 3(b)], the latter indicating the same cumulative dose effect as mentioned before. The results of this experiment demonstrate a linear correlation between the administered compound concentration and their associated fluorescence SIs. Thus, different concentrations of a fluorescent compound can be distinguished by measuring the fluorescence intensity in the eye of a mouse.
In addition, we examined if the PK measurements of ICG through the animal’s eye can be combined with the whole body fluorescence imaging. This approach would facilitate the simultaneous measurement of blood kinetics with biodistribution kinetics. For this experiment, a single SHO mouse was injected with 10 μg ICG/100 μl PBS i.v. and the fluorescent signals were acquired in both eyes and the liver over the time period of 6 min [Fig. 4(a) and Video 4]. The results indicate an immediate increase followed by a sharp decline of the fluorescence SI in both eyes (left: \( t_{\max} = 9 \text{ s}, t_{1/2} = 1.3 \text{ min}; \) right: \( t_{\max} = 7 \text{ s}, t_{1/2} = 1.2 \text{ min} \) [Fig. 3(b)]. The compound was cleared out of the blood stream and accumulated in the liver within 3 min \( t_{\max} = 186 \text{ s} \), as described in the literature. \(^{11,15}\)

3.2 Method Evaluation with OsteoSense750

The fluorescent-labeled bone targeting agent OsteoSense750 was also applied to evaluate the new eye imaging method. This molecule has already been used to examine osteoblastic activity in animal models. \(^{16}\) It has a half-life of 20 to 30 min in mice\(^ {17} \) and rats,\(^ {18} \) depending on the mode of application.\(^ {19,20}\)

The bone (tibia) contains the highest concentration of all the tissues examined and the remainder is excreted via the kidney.\(^ {16,20}\) In contrast to the previous studies, our setup allows simultaneous semiquantitative measurement of blood level and bone uptake simultaneously. Both parameters were recorded over the time period of 1.4 h. The acquired distribution kinetic of OsteoSense750 demonstrates a transient accumulation in the kidneys and an immediate accumulation in the spine [Fig. 5(a)]. Based on the optical imaging measurements \( t_{\max} \) was determined to be 3.8 min and half-life in the blood was 34 min [Fig. 5(b)]. These results correlate with the published data.\(^ {17,18}\)

A final image, taken 24 h after the i.v. injection of the compound, showed a strong fluorescence signal in spine, right and left femur, scapula, ribs, and in the knees [Fig. 5(a)].

3.3 Evaluation with Trastuzumab-Alexa750

Beside the application of small molecules for method evaluation, we also noninvasively investigated the PK behavior of the labeled therapeutic antibody Trastuzumab by eye imaging. Therefore, Alexa750-labeled Trastuzumab was injected in an SHO mouse and monitored over time [Fig. 6(a)]. The fluorescence SIs reached the maximum after 6 s and antibody half-life was 2.5 days [Fig. 6(b)], which is comparable to conventionally acquired and published values.\(^ {12,21}\)

3.4 Evaluation with the F(ab\(^ '\))\(_2\)-Alexa750 Fragment of Trastuzumab

Having confirmed the correspondence between classical PK measurements and fluorescence imaging for ICG, OsteoSense, and Trastuzumab, we further evaluated the F(ab\(^ '\))\(_2\) fragment of Trastuzumab in more detail. This study was prioritized because antibody fragments are considered to penetrate tumor tissue more easily and thus represent optimal targeting moieties.\(^ {22,23}\)

In addition, a direct comparison of the half-life between the eye imaging method and the “gold standard” of blood sampling analysis was performed. The F(ab\(^ '\))\(_2\)-Alexa750 was injected i.v. into SHO mice \((n = 8)\) and the fluorescence intensities were measured in the eye over time. The imaging results showed a high measurement reproducibility between the individual animals and also a low standard deviation for all time points [Figs. 7(a) and 7(b)]. The determined half-life of the labeled compound was 8.3 h, which is in accordance with the published data.\(^ {24}\) Furthermore, the direct comparison of the fluorescence SIs from eye imaging and the analyzed F(ab\(^ '\))\(_2\) protein concentration in the blood (performed by ELISA), revealed a strong linear relationship [Fig. 7(c)]. Linear regression analysis between three measurement time points of both techniques
(3, 8, and 24 h after compound injection) resulted in a square correlation coefficient of $R^2 = 0.8254$.

4 Discussion

We evaluated the application of NIR fluorescence eye imaging for the noninvasive estimation of PK parameters. This new approach was validated with four different compounds, including: ICG, OsteoSense750, Trastuzumab-Alexa750, and the Alexa750 labeled F(ab')2 fragment of Trastuzumab. The results demonstrate that the PK parameters, such as $t_{\text{max}}$, and $t_{1/2}$, can easily be determined by measuring the fluorescence SIs in the eyes of anesthetized mice. The half-life values of the different fluorescent compounds are in accordance with the published data and thus indicate that the noninvasive fluorescence eye imaging method provides reliable data.

![Image](https://www.spiedigitallibrary.org/journals/Journal-of-Biomedical-Optics/JBO.19.1.016022.3)

**Video 3** Monitoring the fluorescence SI in the eye of a SHO mouse after three cumulative dose injections of 5, 10, and 15 μg ICG (MPEG, 7.13 MB) [URL: http://dx.doi.org/10.1117/1.JBO.19.1.016022.3].

Furthermore, half-life values received from the fluorescence imaging were compared with the conventional serum analytics by ELISA. We found that the eye fluorescence SIs directly relate to the compound concentration in the blood ($R^2 = 0.8254$). An important aspect that may have influenced the measurements is the manual compound injection. The usage of an automatic injection device will standardize compound application and therefore reduce the measurement variations to a minimum and further improve the imaging results.

This optical imaging method has multiple advantages compared to the conventional PK and biodistribution assay techniques. Manual labor and required time for sample analysis are significantly reduced, mixing up of blood samples is prevented, and the use of nonradioactive materials permits further analysis by routine laboratory methods without the precautions needed with radiochemicals. Furthermore, the number of animals required is significantly reduced and animal bleeding is not necessary anymore, resulting in improved animal conditions following the 3R principle of animal testing.

In addition to $t_{\text{max}}$ and $t_{1/2}$, organ distribution of new compounds can be analyzed simultaneously. Such measurements can provide new insights regarding the time courses of blood clearance and migration to target organs. The semiquantitative information about the location and concentration of labeled substances in the body can be obtained as a function of time, thereby enabling a more profound understanding of its biological effects. This information is crucial to the design of optimized delivery systems and new drugs.

Antibodies that target cellular surface antigens have complex kinetics. When antigen expression is high, half-life is short because the antibody is rapidly cleared from the blood stream through antigen-mab interactions. When the antigen is depleted, clearance decreases and half-life is consequently prolonged.

As the antibody accumulates, a new steady state is reached.

**Video 4** Monitoring the fluorescence SI in the eye and whole body of a SHO mouse after a single i.v. injection of 10 μg ICG (MPEG, 7.27 MB) [URL: http://dx.doi.org/10.1117/1.JBO.19.1.016022.4].
Therefore, it is of interest to (i) perform PK studies in xenografts (not only in tumor-free mice) and (ii) quantify antibody concentration in the blood and in the target tissue to clarify the association between tumor burden/target expression and saturation kinetics with serum/plasma kinetics. Knowledge of these parameters (measured simultaneously) would provide a more comprehensive data basis for PK–PD modeling which has become an integral part of the preclinical and clinical developments of protein drugs. In addition, combined measurement of PK and target saturation supports strategies to modify serum half-life of therapeutic proteins. In such cases where the clearance of drugs from the specific tissue/organ is fast, conventional noninvasive fluorescence monitoring in the eye and whole body biodistribution kinetics in a SHO mouse after a single i.v. injection of 2 nMol OsteoSence750. Images were recorded with a rate of 1 frame/s over a time period of 83 min. (a) White light picture of the mouse with the measurement region over the eye (inset yellow box). Snap shots of fluorescence images at indicated time points demonstrating fluorescence signals in the kidneys (at $t_{\text{max}}$) and subsequently accumulation in bone tissue (at $t_{1/2}$ and $t_{\text{end}}$). After 24 h of incubation the postmortem image ($t_{24\text{h}}$) demonstrates specific accumulation of the bone targeting agent in spine, femur, scapula, ribs and knees (skin was removed). All raw data images were converted into pseudocolor as shown in the color bar. (b) The diagram illustrates the curve shape of the average fluorescence SI in the ROI. The time to reach the maximum SI ($t_{\text{max}} = 3.8 \text{ min}$) and the half-life value of OsteoSense750 ($t_{1/2} = 34 \text{ min}$) were extracted from the diagram.

Fig. 6 Noninvasive fluorescence monitoring of blood drug levels in the eye and whole body biodistribution kinetics in a SHO mouse after a single i.v. injection of 50 $\mu$g Trastuzumab-Alexa750. Images were recorded with a rate of 1 frame/s over a 15-min time period. Thereafter, daily single measurements were performed for seven time points. (a) White light picture of the mouse with the ROI over the eye (inset yellow box). Snap shots of fluorescence images at indicated time points demonstrating antibody injection, distribution, accumulation and clearance. All raw data images were converted into pseudocolor as shown in the color bar. (b) The diagram illustrates the curve shape of the average fluorescence intensity in the ROI. The maximum SI of Trastuzumab-Alexa750 was reached 6 s after compound injection and half-life was 2.5 days.
techniques cannot catch up with its dynamic changes. Therefore, a noninvasive in vivo real-time imaging modality for protein drugs in biological matrices like the method described here will timely meet the needs and expedite the step of protein drug development.

Furthermore, new antibody formats, glycoengineered antibodies, and antibody drug conjugates can be easily labeled with a fluorochrome and thus can also be examined with our method. However, before performing any in vivo studies with labeled drugs, functional assays must demonstrate that there is no difference in the binding constants and biological effects compared to the nonlabeled substance. For compounds where the labeling with fluorochromes may interfere with the biological characteristics (e.g., receptor binding), optical imaging cannot be applied for assessing PK and biodistribution.

Although planar reflectance optical imaging is associated with the limited tissue penetration, scattering of the emitted fluorescence and the different optical properties of the tissue, such measurements still allow a semi-quantitative assessment and thus, facilitate the selection of the most appropriate time points for taking serum and tissue extraction. With the advent of tomographic optical systems or the combination with CT, such problems can be circumvented and will subsequently improve PK studies using whole body optical imaging. Such hybrid systems will also facilitate studies aiming to address the target mediated clearance and penetration of targeting antibodies into tumor tissue.

The noninvasive measurement of PK parameters by eye imaging provides the possibility to understand PK and PD properties of drugs in a better way. Since fluorescent-labeled compounds (ICG) are already approved as diagnostic markers in humans, there are no restrictions to use our imaging method in a clinical setting. The preclinical to clinical transfer of such biological information and pharmacological data would enhance the drug discovery and development process and can have profound implications on the drug approval process, reducing time, cost, and failure rates in later-stage clinical trials.

5 Conclusions

We describe a new noninvasive optical imaging method that allows monitoring the drug levels in blood and organ distribution simultaneously in mice over the time. We demonstrated the utility of this approach by evaluating four different compounds, including: (i) ICG, a fluorescent dye; (ii) OsteoSence750, a fluorescence-labeled bisphosphonate targeting bone tissue; (iii) Alexa750 labeled Trastuzumab; and (iv) Alexa750 labeled F(ab')2 fragment of Trastuzumab. Our results demonstrate that t_{1/2} and t_{max} can be easily acquired by measuring the fluorescence SIs in the eyes of anesthetized animals. In contrast to the conventional techniques, this new approach improves the performance of PK studies since quantification of the drug in serum probes and data interpolation between time points is not necessary. Furthermore, the number of required mice is significantly reduced and mice do not need to be sacrificed. Whole body planar reflectance optical imaging, besides its limitations, can be applied to get information regarding the distribution of labeled drugs and its accumulation in target tissue. For drugs that do not
emit fluorescence by themselves, labeling with an appropriate fluorescence dye can easily be done. However, initiation of such studies is only justified if biological identity (no difference between labeled and nonlabeled drugs) has been demonstrated. Optimization of hardware and software components in combination with the new fluorescent probes may allow this technology to be applicable in the clinical situation.

Acknowledgments

The authors wish to express their gratitude to A. Wessner for fluorescence labeling of Trastuzumab, U. Jucknischke for performing the Biocare studies, and U. Haupt for cell culturing and mice handling. The constant support of R. Vogel, C. Klein, and M. Weidner and especially of C. Meisel and K. Bossetl is very much appreciated. This work is dedicated to our colleague Steffen Strobel who died from the consequences of an accident after the finalization of the manuscript.

Competing interest statement: All authors are employees of Roche Diagnostics GmbH, Germany.

References

1. G. R. Jang, R. Z. Harris, and D. T. Lau, “Pharmacokinetics and its role in small molecule drug discovery research,” Med. Res. Rev. 21(5), 382–396 (2001).
2. S. A. Roberts, “Drug metabolism and pharmacokinetics in drug discovery,” Curr. Opin. Drug Discovery Dev. 6(1), 66–80 (2003).
3. L. A. Wittenburg and D. L. Gustafson, “Optimizing preclinical study design in oncology research,” Chem. Biol. Interact. 190(2–3), 73–78 (2011).
4. R. E. White and P. Manpitipul, “Pharmacokinetic theory of cassette dosing in drug discovery screening,” Drug Metab. Dispos. 29(7), 957–966 (2001).
5. B. Liu et al., “Snapshot PK: a rapid rodent in vivo preclinical screening approach,” Drug Discovery Today 13(7–8), 360–367 (2008).
6. L. Converti et al., “A new tool for molecular imaging: the microvolumetric beta blood counter,” J. Nucl. Med. 48(7), 1197–1206 (2007).
7. H. Ding and F. Wu, “Image guided biodistribution and pharmacokinetic studies of theranostics,” Theranostics 2(11), 1040–1053 (2012).
8. J. V. Frangioni, “In vivo near-infrared fluorescence imaging,” Curr. Opin. Chem. Biol. 7(5), 626–634 (2003).
9. F. Leblond et al., “Pre-clinical whole-body fluorescence imaging: review of instruments, methods and applications,” J. Photochem. Photobiol. B 98(1), 77–94 (2010).
10. S. A. Hilderbrand and R. Weissleder, “Near-infrared fluorescence: application to in vivo molecular imaging,” Curr. Opin. Chem. Biol. 14(1), 71–79 (2010).
11. C. B. Amooogez et al., “Dynamic contrast-enhanced optical imaging of in vivo organ function,” J. Biomed. Opt. 17(9), 096003 (2012).
12. D. G. Covell et al., “Pharmacokinetics of monoclonal immunoglobulin G1, F(ab’2), and Fab’ in mice,” Cancer Res. 46(8), 3969–3978 (1986).
13. T. Desmettre, J. M. Devoisselle, and S. Mordon, “Fluorescence properties and metabolic features of indocyanine green (ICG) as related to angiography,” Surv. Ophthalmol. 45(1), 15–27 (2000).
14. V. Saxena, M. Sadoqi, and J. Shao, “Polymeric nanoparticulate delivery system for indocyanine green: biodistribution in healthy mice,” Int. J. Pharm. 308(1–2), 200–204 (2006).
15. P. Baungartner, “The handling of indocyanine green by the liver,” Schweiz. Med. Wochenschr. 105(17 Suppl.), 1–30 (1975).
16. A. Zehrer et al., “In vivo near-infrared fluorescence imaging of osteoblastic activity,” Nat. Biotechnol. 19(12), 1148–1154 (2001).
17. P. T. Daley-Yates and R. Bennett, “A comparison of the pharmacokinetics of 14C-labelled APD and 99mTc-labelled APD in the mouse,” Calcif. Tissue Int. 43(2), 125–127 (1988).
18. M. Pongchaidecha and P. T. Daley-Yates, “Clearance and tissue uptake following 4-hour and 24-hour infusions of pamidronate in rats,” Drug Metab. Dispos. 21(1), 100–104 (1993).
19. A. Hoffman et al., “Mode of administration-dependent pharmacokinetics of bisphosphonates and bioavailability determination,” Int. J. Pharm. 220(1–2), 1–11 (2001).
20. D. Kumar et al., “Evaluation of biodistribution by local versus systemic administration of Tc-99m-labeled pamidronate,” J. Orthop. Sci. 11(5), 512–520 (2006).
21. G. Pavlinkova et al., “Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts,” J. Nucl. Med. 40(9), 1536–1546 (1999).
22. P. G. Adams et al., “Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu,” Br. J. Cancer 77(9), 1405–1412 (1998).
23. U. B. Nielsen et al., “Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity,” Cancer Res. 60(22), 6434–6440 (2000).
24. H. Sakahara et al., “Radioimmunomaging using F(ab’)2 fragment of monoclonal antibodies against human alpha-fetoprotein,” Kaku Igaku 22(3), 377–382 (1985).
25. D. Dayde et al., “Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20,” Blood 113(16), 3765–3772 (2009).
26. K. McLarty et al., “Associations between the uptake of (111)In-DTPA-Trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts,” Eur. J. Nucl. Med. Mol. Imaging 36(1), 81–93 (2009).
27. B. A. Ploeger, P. H. van der Graaf, and M. Danhof, “Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling,” Drug Metab. Pharmacokinet. 24(1), 3–15 (2009).
28. L. K. Roskos et al., “PK-PD modeling of protein drugs: implications in assay development,” Bioanalysis 3(6), 659–675 (2011).
29. R. E. Kontermann, “Strategies to extend plasma half-lives of recombinant antibodies,” Biodrugs 23(2), 93–109 (2009).
30. W. Wang, E. Q. Wang, and J. P. Balthasar, “Monoclonal antibody pharmacokinetics and pharmacodynamics,” Clin. Pharmacol. Ther. 84(5), 548–558 (2008).
31. P. Hellager and P. J. Hudson, “Engineered antibody fragments and the rise of single domains,” Nat. Biotechnol. 23(9), 1126–1136 (2005).
32. A. L. Nelson, “Antibody fragments hope and hype,” Multi-Agent-Based Simul. 2(1), 77–83 (2010).
33. T. A. Millward et al., “Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice,” Biotechnol. Biother. 36(1), 41–47 (2008).
34. E. Boghaert et al., “Evaluation of pharmacokinetic values of calicheamicin-antibody conjugates in mice by plasmon resonance analysis of small (5 μl) blood samples,” Cancer Chemother. Pharmacol. 61(6), 1027–1035 (2008).
35. K. O. Vasquez, C. Casavant, and J. D. Peterson, “Quantitative whole body biodistribution of fluorescent-labeled agents by non-invasive tomographic imaging,” PLoS One 6(6), e20594 (2011).
36. A. Le et al., “FMTC-XCT: in vivo animal studies with hybrid fluorescence molecular tomography-X-ray computed tomography,” Nat. Methods 9(6), 615–620 (2012).
37. S. Kunjachan et al., “Noninvasive optical imaging of nanomedicine biodistribution,” ACS Nano 7(1), 252–262 (2013).
38. M. A. Tabrizi, C. M. L. Tseng, and L. K. Roskos, “Elimination mechanisms of therapeutic monoclonal antibodies,” Drug Discovery Today 11(1–2), 81–88 (2006).
39. G. M. Thurer, M. M. Schmidt, and K. D. Wittrup, “Factors determining antibody distribution in tumors,” Trends Pharmacol. Sci. 29(2), 57–61 (2008).
40. A. E. Spinielli et al., “Optical imaging of radioisotopes: a novel multimodal approach to molecular imaging,” Q. J. Nucl. Med. Mol. Imaging 56(3), 280–290 (2012).
41. Q. Zhou and J. M. Gallo, “The pharmacokinetic/pharmacodynamic pipeline: translating anticancer drug pharmacology to the clinic,” AAPS J. 13(1), 111–120 (2011).

Biographies of the authors are not available.

Dobosz et al.: Noninvasive measurement of pharmacokinetics by near-infrared fluorescence imaging...